查看更多>>摘要:The inconsistent findings concerning the effects of vitamin D supplementation on cardiometabolic risk fac-tors and the large heterogeneity in the published literature call for further research to identify sources of heterogeneity and potential effect modifiers.We performed a meta-analysis of randomized controlled tri-als(RCTs)published until March 2024 that reported estimates for the effects of vitamin D supplementation on cardiometabolic factors and relevant baseline covariates of RCT participants.A total of 17 656 partici-pants from 99 RCTs were analyzed,and weighted mean differences(95%confidence intervals(CI))for the intervention status were derived using random-effects modeling.Overall,compared with the placebo,vitamin D supplementation(median dose:3320 international unit(IU)·day-1;range 40-120 000 IU·day-1)had favorable effects on systolic blood pressure(SBP;-2.04(95%CI,-3.50,-0.59)mmHg;1 mmHg=0.133 kPa),diastolic blood pressure(DBP;-3.00(95%CI,-3.61,-2.39)mmHg),total cholesterol(TC;-0.12(95%CI,-0.21,-0.03)mmol·L-1),fasting blood glucose(FBG;-0.13(95%CI,-0.20,-0.05)mmol·L-1),hemoglobin A1C(A1C;-0.09%(95%CI,-0.13%,-0.05%)),and fasting blood insulin(FBI:-7.61(95%CI,-11.93,-3.30)pmol·L-1).The benefits of vitamin D were most evident in trials performed in non-Westerners,participants with baseline 25-hydroxyvitamin D(25[OH]D)lower than 15.0 ng·mL-1,non-obese(body mass index(BMI)<30 kg·m-2),and older(age ≥ 50 years).The findings of this study underscore the need for personalized vitamin D intervention strategies that comprehensively account for individual patient characteristics(such as ethnocultural background,age,BMI,and circulating 25[OH]D level),intervention dosage,and intervention duration to optimize cardiometabolic health outcomes.